[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Okuvision GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100633841","safety-and-clinical-applicability-of-transcorneal-electrical-stimulation-tes-in-geographic-atrophy-100633841",false,"NCT07531927","Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy","Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy Under Everyday Conditions - a Multicentric, Randomized, Double-masked, Sham-controlled Pilot Study","TES-GAP","Inclusion criteria:\n\n* Willing and able to understand the study and provide informed consent\n* 60 years of age or older\n* Diagnosis of geographic atrophy due to age-related macular degeneration confirmed by imaging\n* The affected area in the eye must be within a defined size range and clearly visible on imaging\n* Eye conditions must allow for good-quality images and reliable measurements\n* Must have a minimum level of visual acuity\n* Women of childbearing potential must have a negative pregnancy test, and must agree to use effective contraception during the study (women who are postmenopausal or surgically sterile are not subject to pregnancy-related requirements)\n\nExclusion criteria:\n\n* History or presence of certain eye conditions (e.g. macular edema, abnormal blood vessel growth or related conditions, retinal detachment, blood vessel blockage) in the study eye\n* Previous major eye surgeries (including retinal surgery or vitrectomy)\n* Previous laser treatment or injections in the study eye\n* Any other eye condition that could interfere with vision tests, imaging or study results\n* Planned eye surgery during the study period\n* Recent treatment with investigational drugs for geographic atrophy\n* Presence of active medical implants\n* Serious or uncontrolled systemic diseases, history of epilepsy or poor general health or conditions affecting the ability to follow study procedures\n* Participation in another clinical study recently or at the same time\n* Breastfeeding, relevant allergies (e.g. to silver), or heavy smoking","ALL","60 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot study is to evaluate the safety and the effectiveness of transcorneal electrical stimulation (TES) therapy with the OkuStim 2 System in patients with geographic atrophy (GA).\n\nResearchers will compare the effects of two different electrical stimuli with a placebo to see if the stimuli are safe and can slow down the progression of the disease.\n\nParticipants will be randomly assigned to one of these three groups:\n\n* TES-treatment with a rectangular stimulus\n* TES-treatment with a repetitive ramp stimulus\n* Placebo (sham) treatment\n\nParticipants will apply the therapy at home, once a week for 30 minutes each over a duration of 1 year.",[27],"Geographic Atrophy Secondary to Age-related Macular Degeneration",[29,30,31,32,33,34,35,36,37],"TES","TcES","OkuStim","OkuStim 2","Okuvision","Electrical Stimulation","Transcorneal Electrical Stimulation","Geographic Atrophy","AMD","RECRUITING","2026-05-06",{"date":41,"type":42},"2026-05-07","ACTUAL",{"date":44,"type":42},"2026-05-05",{"date":46,"type":21},"2028-06",{"name":48,"class":49},"Okuvision GmbH","INDUSTRY",5,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100635150","observational-study-to-investigate-the-short-term-effects-of-transcorneal-electrical-stimulation-on-visual-performance-100635150","NCT07548944","Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance","Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation (TES) on Visual Performance in Patients With Retinitis Pigmentosa and Similar Retinal Diseases","TES-STEP","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease\n* Current treatment with TES using the OkuStim® System within the intended purpose\n* Subjective perception of short-term effects after TES treatment\n* Ability and willingness to give informed consent\n\nExclusion Criteria:\n\n* Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation\n* Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments\n* Simultaneous participation in other clinical studies that could influence the results of the study\n* Severe comorbidities that could compromise patient safety or study conduct","18 Years",{"count":61,"type":21},30,"OBSERVATIONAL","Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.",[65,66,67],"Retinitis Pigmentosa (RP)","Usher Syndrome","Cone Rod Dystrophy",[35,29,31,33,69,70,71,72,73],"Retinitis pigmentosa","Eye Diseases","Retinal Dystrophies","Retinal Degeneration","Retinal Diseases","2026-04-30",{"date":76,"type":42},"2026-05-01",{"date":78,"type":42},"2026-04-20",{"date":80,"type":21},"2027-03",{"name":48,"class":49},1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":82},"100568571","transcorneal-electrical-stimulation-for-the-treatment-of-visual-field-defects-in-patients-with-open-angle-glaucoma-100568571","NCT06682962","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma - a Monocentric, Randomized, Double-Masked, Sham-Controlled Pilot Study","TES-GPS","Inclusion Criteria:\n\n1. Willingness to participate in the study, the subjects signed and dated informed consent must be submitted before the start of the screening\n2. Age ≥ 40 years\n3. Primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma (according to the EGS criteria) in the study eye\n4. Current progression in perimetry of at least 1.5 dB per year in the study eye and mean defect (MD) in the study eye between ≥ 6 and ≤ 12 dB (Octopus visual field) or ≤ -6 and ≥ -12 dB (Humphrey visual field) in the screening examination as the mean value of the two visual field examinations carried out as part of the screening (permitted deviation maximum 2 dB)\n5. Visual acuity ≥ 0.2 decimal in the study eye (corresponds to a visual acuity of 0.7 logMAR)\n6. The patient must master home stimulation after extensive training.\n7. Ability of subject to understand the scope, significance and individual consequences of participation in the study\n8. Ability of subject to give consent\n9. If both eyes meet the inclusion\u002Fexclusion criteria, the eye with the higher MD is selected as the study eye. If the MD is the same in both eyes, the eye with the worse visual acuity will be selected as the study eye. If there is no difference between the eyes, the right eye will be selected as the study eye\n10. Negative serum or urine pregnancy test at screening in women of childbearing potential. Participants are considered to be of nonchildbearing potential if they are postmenopausal and have not menstruated for at least 12 months prior to screening or if they are surgically sterile\n11. Women of childbearing potential must agree to be abstinent or to use highly effective methods of contraception that result in a failure rate of less than 1% per year. This applies consistently throughout the duration of the treatment once you have given your consent to participate in the study.\n\nExclusion Criteria:\n\n1. Neovascularisations of any origin in the study eye\n2. Condition after arterial or venous occlusions in the study eye\n3. Condition after intraocular surgery in the last 3 months before the screening examination in the study eye\n4. Acute (intra)ocular inflammation in any eye\n5. Non-proliferative or proliferative diabetic retinopathy in the study eye\n6. Condition after retinal detachment in the study eye\n7. Dry age-related macular degeneration affecting the visual field in the study eye\n8. Exsudative age-related macular degeneration in the study eye\n9. Macular edema of any origin in the study eye\n10. Other relevant retinal diseases in the study eye\n11. Any form of corneal degeneration that limits vision in the study eye\n12. Any disease other than glaucoma affecting the central 30° visual field in the study eye\n13. No cataract surgery or other eye surgery may be planned for the patient in the study eye during the duration of the study (except laser trabeculoplasty)\n14. Patients with active implants\n15. General illnesses that are difficult to control\u002Fadjust and which, in the opinion of the investigator, could jeopardize regular study routines\n16. Poor general condition according to the investigators assessment\n17. Mental illness or dementia, that, in the opinion of the investigator, reduces the understanding of the study procedures and use of the Okustim 2 System\n18. Simultaneous participation in another interventional study or past interventions whose effect may still be ongoing (30 days)\n19. Breastfeeding women\n20. Patients unable to consent\n21. Previous enrolment in the TES-GPS study\n22. Contraindications to the use of OkuStim 2 such as allergies\u002Fhypersensitivity to silver","40 Years",{"count":93,"type":21},50,[24],"Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.\n\nThe aim of this pilot study is to evaluate the safety and effectiveness of the treatment of visual field defects using transcorneal electrical stimulation (TES) with the OkuStim 2 System in patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma.",[97,98,99,100,101],"Glaucoma","Primary Open Angle Glaucoma","Pseudoexfoliation Glaucoma","Pigment Dispersion Glaucoma","Normal Tension Glaucoma",[29,30,103,31,33,97,34],"POAG","2026-03-10",{"date":106,"type":42},"2026-03-12",{"date":108,"type":42},"2025-04-02",{"date":46,"type":21},{"name":48,"class":49},""]